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Abstract
Background: Timely initiation of antiretroviral treatment (ART) requires sustained engagement in HIV care before
treatment eligibility. We assessed loss to follow-up (LTFU) correlates in HIV-positive adults accessing HIV treatment
and care, not yet ART-eligible (CD4 >500 cells/mm3).
Methods: This was a sub-study of a prospective cohort study (focusing on sexual behaviour) in an area of high HIV
prevalence and widespread ART availability in rural KwaZulu-Natal, South Africa. Psychosocial, clinical and
demographic data were collected at recruitment from individuals with CD4 >500 cells/mm3. LTFU was defined as
not attending clinic within 13 months of last visit or before death. Individuals starting ART were censored at ART
initiation. Data were collected between January 2009 and January 2013. Analysis used Competing Risks regression.
Results: Two hundred forty-seven individuals (212 females) were recruited (median follow-up 2.13 years, total
follow-up 520.15 person-years). 86 remained in pre-ART care (34.8 %), 94 were LTFU (38.1 %), 58 initiated ART
(23.5 %), 7 died (2.8 %), 2 transferred out (0.8 %). The LTFU rate was 18.07 per 100 person-years (95 % CI 14.76–21.12).
LTFU before a competing event was 13.5 % at one and 34.4 % at three years. Lower LTFU rates were significantly
associated with age (>37 versus ≤37 years: adjusted sub-Hazard ratio (aSHR) 0.51, 95 % CI 0.30–0.87), openness with
family/friends (a little versus not at all, aSHR 0.81, 95 % CI 0.45–1.43; a lot versus not at all, aSHR 1.57, 95 % CI 0.94–2.62),
children (0 versus 4+, aSHR 0.68, 95 % CI 0.24–1.87; 1 versus 4+, aSHR 2.05 95 % CI 1.14–3.69, 2 versus 4+; aSHR 1.71,
95 % CI 0.94–3.09; 3 versus 4a, aSHR 1.14, 95 % CI 0.57–2.30), previous CD4 counts (1 versus 0, aSHR 0.81, 95 % CI 0.45–
1.43; 2+ versus 0, aSHR 0.43, 95 % CI 0.25–0.73), and most recent partner HIV status (not known versus HIV-positive,
aSHR 0.77, 95 % CI 0.50–1.19; HIV-negative versus HIV-positive, aSHR 2.40, 95 % CI 1.18–4.88). The interaction between
openness with family/friends and HIV partner disclosure was close to significance (p = 0.06). Those who had neither
disclosed to partners nor were open with family/friends had lowest LTFU rates.
Conclusions: Strategies to retain younger people in pre-ART care are required. How openness with others, partner HIV
status and disclosure, and children relate to LTFU needs further exploration.
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Background
With an estimated 6.4 million people, South Africa has
the world’s largest HIV-positive population [1]; among
adults aged 15–49, HIV prevalence is estimated at
18.6 %. South Africa’s public sector antiretroviral (ART)
programme began in 2004 and by the end of 2012 over
two million were on treatment [1]. Even with expanded
global ART guidelines [2], however, significant numbers
remain ART-ineligible in countries such as South Africa
not currently recommending treatment for all people
living with HIV. Retention in care in this group is im-
portant for timely future ART initiation. Understanding
loss-to-follow-up (LTFU) (non-attendance at scheduled
clinic visits) from pre-ART care is also important for
test-and-treat interventions [3].
Despite lower mortality rates, overall attrition (com-
bined LTFU, death and transfer to another programme)
for those ART ineligible is higher than for those
ART-eligible [4]. Median attrition rates of 54 % (across
studies with follow-ups from 7 months to 5 years) have
been reported in sub-Saharan Africa (SSA) [5, 6]. Most
studies have used a cut-off of CD4 <200 cells/mm3
for ART-eligibility [4] although South Africa guidelines for
ART initiation in South Africa rose to CD4 counts
of <500 cells/mm3 in January 2015, consistent with WHO
guidelines at that time [7].
There have been few studies of LTFU correlates in
SSA for individuals not yet ART-eligible, particularly
those with a CD4 count of >500 cells/mm3. A clearer
understanding of LTFU in this group may help develop
targeted interventions to enhance programme retention.
In South Africa, one study examined LTFU in adults
(n = 4223, 84 % female) 13 months after an initial
CD4 count of ≥200 cells/mm3 [8]. Higher LTFU levels
were independently related to being employed, male,
younger age, higher initial CD4 count, out-migration
and greater household size. Thirty five per cent of in-
dividuals with an initial CD4 count of >500 cells/mm3
were retained in care. Elsewhere in South Africa [9],
among 356 individuals newly enrolled in pre-ART
care (CD4 count ≥250 cells/mm3), higher LTFU levels
at one year were related to unemployment and higher ini-
tial CD4 count. As LTFU was more common in those with
higher CD4 counts in both of these studies, there is a need
to assess correlates of engagement in individuals before
symptoms develop. In a third study, in Kenya [10], with
530 individuals with an initial CD4 count of ≥200 cells/
mm3, higher LTFU levels at six months after registration
in HIV care, were related to greater distance from a main
road and being unmarried.
We were unable to find research on psychosocial
correlates of LTFU in pre-ART care. Understanding
these relationships may enable researchers to suggest
why distal factors such as gender and employment
are associated with LTFU. Psychosocial variables may
be more amenable to intervention than structural or
demographic factors. We recently found that, in those
ART-eligible, higher LTFU rates were related to male
sex, social support (increased openness and less reliance on
family and friends), social capital (believing that community
problems would be solved at higher levels, e.g., traditional
and district leaders rather than individuals and neighbours),
younger age and having children [11]. Predictors of LTFU
in those not yet eligible for ART may be different.
We used data from a prospective cohort study of
individuals recruited from HIV care clinics with a CD4
count of ≥500 cells/mm3 and not yet ART-eligible, in an
area of high HIV prevalence and widespread ART avail-
ability in KwaZulu-Natal, South Africa [12, 13] to explore
the associations between psychosocial, demographic and
clinical variables and LTFU.
Methods
Study design and location
The study used a prospective cohort design [12] with re-
cruitment between January 2009 and April 2011 and
follow-up until January 2013. It took place in the Hlabisa
sub-district of uMkhanyakude, in rural northern
KwaZulu-Natal, South Africa, an area with an HIV adult
prevalence estimate of 24 % [14]. One third of this
sub-district covers the Africa Centre Demographic
Surveillance Area (DSA) (http://www.africacentre.ac.za/).
The HIV treatment and care programme began in
2004 and is large scale and decentralized [15]. It imple-
ments national HIV treatment guidelines, which until
April 2010 denoted ART-eligibility at CD4 count ≤200
cells/mm3 or WHO stage 3 or 4 [16], between April
2010 and August 2011, CD4 count ≤350 cells/mm3 for
pregnant women, active TB, WHO stage 3 or 4 condition
[17], and from August 2011 until the end of the study
period in January 2013, CD4 count <350 cells/mm3,
MDR-TB patients, and all HIV positive pregnant or
breastfeeding women [18]. Within the sub-district,
sharing household membership or living arrangements
with individuals in HIV treatment and care is com-
mon [19], with HIV disclosure to an average of four
family and friends for women and just over three
family and friends for men [20].
Pre-ART care at the time of the study included CD4
count testing, individual counselling (with advice on
healthy living, disclosure, partner notification and test-
ing, transmission risk reduction and family planning)
and peer support groups [8]. National guidelines at the
time of the study recommended that individuals with
CD4 counts of ≥500 cells/mm3 should attend clinic
every 12 months for repeat clinical assessment and CD4
counts [21]. Practice varied, however, and often the
study clinics advised return after 6 months [8].
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Participants
Participants were HIV-positive individuals taking part in
a prospective cohort study [12] and (a) with CD4 count
≥500 cells/mm3 at the time of recruitment and thus not
yet eligible for treatment [16–18] (b) ≥18 years (c) at-
tending one of three study HIV clinics.
Potential participants were excluded if they were cur-
rently pregnant (as the primary focus of the prospective
cohort study [12] was on sexual behaviour), planned to
leave the area within 12 months or had previous ART
use for ≥2 weeks. All individuals meeting the inclusion
criteria were approached. Individuals were recruited
after receiving a CD4 count of ≥500 cells/mm3. Written
consent was given for participation with separate con-
sent to link study data with HIV treatment and care
programme and surveillance data.
Measurement of variables
Analysis used variables from (1) a baseline interview at
recruitment: questions were translated into isiZulu and
backtranslated into English to ensure equivalence of
meaning [12, 13], (2) routinely held programme data
held in a monthly updated database and (3) surveillance
data: demographic information collected biannually
from households and individuals and entered into a
database for the approximately 90, 000 individuals
within the area [22].
Variables were chosen due to their potential associ-
ation with LTFU. The main psychosocial variables from
the baseline interview were:
1. Stigma
Twenty-four questions adapted from Sayles et al.
[23] (e.g., ‘I feel ashamed to tell people that I have
HIV’). Scores were added to form a scale with a total
score (out of 72) (α = 0.75).
2. Social support
Five questions, derived from Myer et al. [24],
covering frequency of contact with, and reliance on,
family members/friends, personal disclosure to
friends/family, and the availability of confidants.
They were considered as separate questions due to
differences in response options and low inter-item
correlations.
3. Social capital
This refers to an individual’s connections (structural)
and trust/reciprocity (cognitive) with others [25].
Questions were based on Pronyk et al. [26]. Three
structural questions asked about frequency of time
spent with neighbours, frequency of neighbourhood
crime and community group participation. Two
cognitive questions asked about neighbours’
commitment to community projects, and problem-
solving for community problems. These questions
were considered separately due to differences in
response options and low inter-item correlations.
4. Antiretroviral therapy
a. Personal knowledge of others taking ART
(one question)
b. HIV optimism. One question (adapted from
Elford et al. [27]) - ‘I am less worried about HIV
now that treatment is available’.
c. ART/HIV knowledge. Eight questions
(e.g., ‘Sometimes ART can cause side effects
that make people feel worse’). Scores were
added to form a scale with a total score
(out of 24) (α = 0.55).
5. Relationship quality
Ten questions, adapted from the 24-item Social
Provision Scale [28], were used for those in a current
relationship (α = 0.66).
Other variables collected on recruitment
The following were recorded from the baseline inter-
view: age, gender, time since HIV diagnosis, marital
status, religious affiliation and importance, most re-
cent partner characteristics (age differential, place of
residence, HIV disclosure to partner and HIV status),
government grants, number of current sexual rela-
tionships, employment, clinic, extent of HIV disclos-
ure (number of categories of people disclosed to, e.g.
partner, friend, family), HIV partner disclosure, and
reason for HIV testing (responses grouped into (a)
self-initiated: non-sickness, e.g., wanted to know status
(b) self-initiated sickness, e.g., having symptoms (c)
other-initiated, e.g., tested at antenatal clinic). Highest
educational level, migration and number of children
were recorded from the surveillance database and
CD4 count at recruitment (converted into quartiles)
and number of previous CD4 counts were recorded
from the programme database.
Outcomes
The programme database was used to define outcomes,
with verification by cross-checking with surveillance and
study databases. Participants were LTFU if they had not
attended an HIV treatment and care programme clinic
(a) in the last 13 months (i.e., more than one month late
for scheduled CD4 re-testing), or (b) in the 13 months
before death, and had not transferred out of the
programme. Attendance could be at any of the 17 pri-
mary health care facilities within the programme. The
entry date was the date of recruitment. The end of ob-
servation date was the ART initation date, the death date
(if LTFU criteria were not met or ART had not been
started before death) or the last clinic date for those
transferred out. Those retained in the programme were
censored at the study end date (13th January 2013).
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Two methods were considered to calculate the end of
observation date for those LTFU (both used in previous
studies [10, 29, 30]):
1. Censoring at last clinic date (last clinic date method)
2. Censoring at the midpoint between last clinic date
and next scheduled clinic date, i.e, estimating a
mean actual LTFU date (midpoint method).
Thirty-four participants last attended clinic before
their baseline interview date. That is, these individuals
did not return to clinic for further CD4 cell count test-
ing but did return for their baseline interview shortly
after they had received their CD4 result that determined
their treatment ineligibility (median duration between
last clinic date and baseline interview for this group:
14 days, interquartile range (IQR) 13–29.5). These partici-
pants would have been ineligible for analysis using the last
clinic date method because their baseline interview was
after their last clinic visit for CD4 testing, with a resulting
loss of statistical power. As a consequence we used the
midpoint method as this LTFU definition allowed their end
of observation date to be after the baseline interview date.
Analysis
Analysis used STATA 11 [31]. Distributions of four
quantitative variables were examined for normality,
using skew tests. ART knowledge and relationship qual-
ity were skewed (p < 0.01) and thus categorised. Age was
also skewed (p < 0.01) and considered both as age bands
and as a binary variable (≤37 and >37) in univariable
analysis (as the upper two age bands and the lower age
bands had similar estimates). Stigma was normally dis-
tributed (p = 0.15) but this variable was grouped into
quartiles and represented by indicators in models (as a
linearity assumption did not appear reasonable after uni-
variable analysis). We compared demographic and clin-
ical characteristics of the 34 participants who last
attended clinic before their baseline interview and the
remaining 213 participants. There were no statistically
significant differences in demographic or clinical vari-
ables between these groups.
Univariable associations, using Competing Risks re-
gression, were calculated between LTFU and variables at
recruitment. Competing Risks regression is an alterna-
tive to Cox regression for survival data in the presence
of competing risks. This approach models the subhazard
of failure events in the absence of the occurrence of
competing events. Multivariable analysis was conducted,
using Competing Risks Regression, with the inclusion of
sex and age (≤37 and >37 years). Additional variables
were added in descending order of univariable relation-
ship with LTFU if p ≤ 0.15, and were retained if they im-
proved model fit using AIC values. Competing Risks
regression modelling was also carried out using backward
selection and with Wald tests as the criterion for model
selection. Variables included in the final model using these
approaches were also included in a Cox regression multi-
variable model to facilitate comparison between the two
methods of regression. The proportionality of subhazards
was examined in the Competing Risks regression model
by examining time interactions. Cumulative incidence
curves were used to plot the cumulative incidence
function from the Competing Risks regression model. The
proportional hazards assumption was tested in the Cox re-
gression model by examining Schoenfeld residuals [32].
Results
There were 247 participants (212 (85.8 %) female, 35
(14.2 %) male). The median follow-up time was
2.13 years (IQR 1.12–3.00), total study follow-up
time 520.15 person-years. Median age was 34 years
(IQR 27–43), and median CD4 count 631.5 cells/mm3
(IQR 559–768 cells/mm3) at recruitment. Ninety-five par-
ticipants (38.5 %) had not received a previous CD4 test re-
sult prior to the baseline CD4 test (median number of
previous CD4 tests 1, IQR 0–2).
Programme LTFU
The process of determining LTFU outcome is presented
in Fig. 1. The midpoint between the last clinic visit
attended and the next scheduled clinic visit (12 months
later) was 183 days. Ninety-four individuals were LTFU
(38.1 %). The overall LTFU rate was 18.07 per 100
person-years (95 % CI: 14.76–21.12). Eighty-six individ-
uals remained ART-ineligible but not LTFU (34.8 %), 58
initiated ART (23.5 %: median time to initiation from re-
cruitment in this group 1.89 years: IQR 1.39–2.65),
seven died (2.8 %) and two transferred out (0.8 %). LTFU
before a competing event was 13.5 % at one year and
34.4 % at three years.
Univariable analysis
Univariable analyses of associations from the Competing
Risks Regression analysis between LTFU and (a) demo-
graphic and clinical variables are presented in Table 1
and (b) psychosocial variables in Table 2. Higher LTFU
rates were related (p < 0.15) to number of children, age
(<37 years), no group participation, fewer previous CD4
counts, increased openness to family and friends, not
living with one’s most recent partner while in a rela-
tionship and the most recent partner being HIV-
negative (Tables 1 and 2). Among participants living
with their most recent partner, LTFU rates were simi-
lar irrespective of whether they had disclosed to them
(partner disclosure: 14.23 per 100 person-years, 95 % CI
5.94–26.13; no partner disclosure: 12.46 per 100 person-
years, 95 % CI 9.83–20.61).
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Multivariable analysis
In the final main effect model from the Competing Risks
regression analysis (Table 3), higher LTFU rates were in-
dependently associated with younger age, increased
openness with family and friends, fewer previous CD4
counts, most recent partner status being HIV-negative
and number of children. The proportionality of subha-
zards assumption was met. Sex was not significantly as-
sociated with LTFU in the final model (or in univariable
analysis). The same final model was produced regardless
of the method of variable inclusion (forward or back-
ward) and the method of model selection (AIC values or
p values from Wald tests). The Cox regression model
using the same exposures that were retained in the
Competing Risks regression model showed very similar
estimates and p values. Proportional hazards assump-
tions were not violated for any of the variables in the
final Cox regression model or for the model as a whole
(p = 0.60).
To explore the relationship between (a) openness with
family and friends and LTFU (b) most recent partner
HIV status and LTFU, post-hoc Competing Risks regres-
sion analyses examined interactions between openness
with family and friends and most recent partner HIV
status and the following potentially relevant psychosocial
factors: (a) stigma (b) number of categories of people
disclosed to. There were no significant interactions.
Post-hoc analyses also explored interactions between
HIV partner disclosure (based on self-report of having
disclosed to anyone, followed by identifying that a
Fig. 1 Outcome flow diagram
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Table 1 Demographic and clinical variables and loss-to-follow up in pre-ART care
Number (% LTFU)a LTFU rate
(per 100 p-y)
Sub Hazard
Ratiob(95 % CI)
P value of relationship
with LTFU
Age in years <27 55 (49.1) 24.24 1.00 0.07
27–31 51(41.2) 19.55 0.74 (0.42–1.31)
32–37 52 (44.2) 20.98 0.83 (0.48–1.43)
38–44 35 (25.7) 11.20 0.41(0.19–0.89)
>44 54 (25.9) 12.57 0.46 (0.23–0.89)
Age in years (binary) ≤37 158 (44.9) 21.62 1.00 0.01
>37 89 (25.8) 12.00 0.51 (0.32–0.83)
Age in years (continuous) 0.98 (0.96–1.00) 0.07
Sex Female 212 (37.3) 17.29 1.00 0.40
Male 35 (42.9) 23.72 1.27 (0.72–2.23)
Clinic 1 109 (37.6) 17.89 1.00 0.10
2 50 (48.0) 25.87 1.50(0.91–2.47)
3 88 (33.0) 14.63 0.84 (0.53–1.36)
Marital status Never married 199 (40.2) 19.13 1.00 0.20
Ever Married 48 (29.2) 13.72 0.69 (0.39–1.22)
Number of current relationshipsc 0 61 (32.8) 15.95 1.00 0.38
≥1 185 (39.5) 18.51 1.25 (0.76–2.06)
Religion None 19 (31.6) 16.58 1.00 0.42
Zionist 74 (45.9) 20.92 1.34 (0.55–3.27)
Shembe 48 (41.7) 22.77 1.39 (0.54–3.61)
Christian 90 (33.3) 15.64 0.99 (0.40–2.44)
Other 16 (25.0) 9.57 0.62 (0.17–2.25)
Religion importance Not at all 31 (32.3) 14.56 1.00 0.64
Somewhat 49 (36.7) 16.90 1.11 (0.52–2.41)
Very 167 (39.5) 19.13 1.32 (0.68–2.57)
Employment No 198 (37.9) 18.17 1.00 0.95
Yes 49 (38.8) 17.69 1.02 (0.61–1.70)
Government grant (self) No 67 (40.3) 20.26 1.00 0.59
Yes 180 (37.2) 17.32 0.88 (0.57–1.38)
Government grant (household) No 94 (34.0) 15.66 1.00 0.27
Yes 153 (40.5) 19.63 1.27 (0.83–1.94)
HIV diagnosis This month 31 (48.4) 24.32 1.00 0.23
< one year 80 (41.2) 20.18 0.81 (0.44–1.48)
1–2 years 61 (29.5) 12.91 0.52 (0.27–1.00)
3 + years 75 (37.3) 18.01 0.78 (0.42–1.46)
Highest educational leveld <1 year 18 (27.8) 12.28 1.00 0.07
Primary school 67 (29.9) 13.24 1.03 (0.39–2.72)
Secondary, not matric 85 (35.3) 16.82 1.32 (0.52–3.36)
Matric and higher 67 (47.8) 23.95 2.02 (0.80–5.14)
Number of children None 16 (31.3) 15.71 1.25 (0.46–3.38) 0.03
1 child 43 (53.5) 26.28 2.34 (1.32–4.14)
2 children 67 (44.8) 22.15 1.99 (1.13–3.50)
3 children 48 (33.3) 16.60 1.34 (0.69–2.60)
4+ children 73 (27.4) 11.84 1.00
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spouse/non-marital partner had been disclosed to) and:
(a) openness with family and friends (b) most recent part-
ner HIV status. There was an interaction between open-
ness with family and friends and HIV partner disclosure
that was close to significance (p = 0.06). To explore this
further, a composite variable of openness with family and
friends/partner HIV disclosure was created and included
in multivariable analysis along with age, sex, number of
previous CD4 counts, most recent partner HIV status and
number of children (variables from the final model re-
ported in Table 3). Higher LTFU rates were independently
associated with younger age, fewer previous CD4 counts,
most recent partner status being HIV-negative, and num-
ber of children (all with very similar estimates to those
from the final model in Table 3), and the composite open-
ness with family and friends/partner disclosure variable
(Table 4). All categories of openness and partner disclos-
ure appeared to be related to higher LTFU rates than be-
ing not at all open with family and friends and reporting
no partner disclosure. The model with the composite
openness/partner disclosure variable (Table 4) had a lower
AIC value than the model presented in Table 3. Sub-
analyses exploring the interaction between openness with
family and friends and HIV partner disclosure using only
those in a current partnership at recruitment (n = 185),
showed that this interaction reached statistical significance
(p = 0.04). There was not an interaction between most re-
cent partner HIV status and HIV partner disclosure.
Discussion
We assessed the relationship between psychosocial, demo-
graphic and clinical variables and LTFU in HIV-positive
individuals in pre-ART care. As seen in previous studies,
the LTFU rate (38.1 %) was higher than in those eligible
for or initiating ART [4, 11]. Direct comparisons between
pre-ART cohorts and ART cohorts are problematic,
however, as loss to follow-up from ART is conditional
on having started ART.
The association between younger age and higher LTFU
rates is consistent with other studies on pre-ART LTFU
[8, 33] and with studies on those ART-eligible [11, 34].
How age impacts upon LTFU needs clarification. For ex-
ample, beliefs about the consequences of engaging in
care might differ with age [35] or there may be greater
competing demands that impact upon clinic attendance
in younger than in older individuals. Competing de-
mands life activities have been reported as a barrier to
patient retention in other studies [36]. The relationship
between younger age and higher LTFU rates (across
studies that analyse age and calculate LTFU differently)
may have clinical implications. Integrating pre-ART care
with services specific to younger peoples’ needs (e.g., re-
productive health services [37]), could be considered.
Strategies that have a potentially beneficial effect on re-
tention in the pre-ART phase, regardless of age (e.g.,
mobile phone prompts [38], cotrimoxazole prophylaxis
[39], transport vouchers [40], home counselling [41],
and case management [42]), could also be implemented.
The association between greater openness to family
and friends and LTFU was also seen in a parallel cohort
of ART-eligible individuals [11]. Being open with family
and friends may mean that emotional support is offered
by one’s social network rather than sought from clinic
staff. Being open with family and friends may provide
the opportunity for others to provide reassurance to the
individual that clinic attendance is not yet necessary. Fu-
ture research could assess social support more compre-
hensively, or could use a qualitative approach to explore
these possibilities in more depth.
The close to significant interaction between openness
to family and friends and HIV partner disclosure is
worth further examination. Lower LTFU rates among
those not open with family and friends and not having
disclosed their HIV status to a partner, suggests that
clinic attendance may provide an important source of
social support for this group. There have been reported
Table 1 Demographic and clinical variables and loss-to-follow up in pre-ART care (Continued)
CD4 count <560 62 (37.1) 19.38 1.00 0.69
560–631 61 (42.6) 21.88 1.19 (0.69–2.07)
632–768 62 (32.3) 14.13 0.86 (0.48–1.56)
≥769 61 (41.0) 17.74 1.15 (0.65–2.01)
Migration No migration in last 2 years 150 (34.7) 15.84 1.00 0.32
Migration in last 2 years 49 (42.9) 21.77 1.38 (0.82–2.28)
Missing data 48 (43.8) 22.01 1.36 (0.82–2.26)
Number of previous CD4 counts 0 95 (45.3) 22.43 1.00 0.03
1 79 (41.8) 20.11 0.89 (0.57–1.40)
2+ 73 (24.7) 10.95 0.49 (0.29–0.85)
an = 247 unless stated; bCompeting Risks Regression;cn = 246; dn = 237
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Table 2 Psychosocial variables and loss-to-follow up in pre-ART care
Number
(% LTFU)a
LTFU rate
(per 100 p-y)
Sub Hazard
Ratiob(95%CI)
P value of relationship
with LTFU
Stigma (α = 0.75) 0–35 57 (35.1) 17.86 1.00 0.59
36–41 54 (33.3) 14.62 0.82 (0.43–1.55)
42–47 64 (37.5) 16.58 0.92 (0.51–1.66)
48+ 72 (44.4) 22.80 1.19 (0.67–2.10)
Stigma (continuous) 1.00 (0.98–1.03) 0.83
Categories of HIV disclosure 0 34 (47.1) 25.12 1.00 0.52
1 84 (35.7) 17.28 0.73 (0.39–1.34)
2 58 (41.4) 20.43 0.83 (0.44–1.57)
3 + 71 (33.8) 14.51 0.63 (0.34–1.19)
HIV partner disclosure No 91 (35.2) 17.86 1.00 0.58
Yes 156 (39.7) 18.18 1.13 (0.73–1.74)
Testing reason Self-initiated: non sickness 79 (34.2) 16.96 1.00 0.82
Self-initiated: sickness 91 (41.8) 19.83 1.17 (0.71–1.92)
Other initiated 77 (37.7) 17.13 1.05 (0.62–1.78)
Changed sexual behaviour No 78 (42.3) 20.57 1.00 0.42
Yes 169 (36.1) 16.96 0.84 (0.55–1.28)
Knowledge of people on ART No 44 (45.5) 20.92 1.00 0.41
Yes 203 (36.5) 17.43 0.82 (0.51–1.32)
ART knowledge Low (> = 21) 57 (40.4) 20.24 1.00 0.44
Mid (22–23) 52 (42.3) 23.12 1.06 (0.59–1.92)
High (24) 138 (35.5) 15.74 0.80 (0.48–1.31)
HIV optimism No 79 (40.5) 20.85 1.00 0.46
Yes 168 (31.3) 16.91 0.85 (0.55–1.31)
Social support – time with family < once a month/not at all 20 (35.0) 16.50 1.00 0.61
Once a month 58 (41.4) 18.04 1.12 (0.49–2.57)
At least once a fortnight/several
days a week
25 (28.0) 12.20 0.72 (0.26–2.03)
Every day 144 (38.9) 19.49 1.21 (0.55–2.65)
Social support – time with friends < once a month/not at all 74 (32.4) 14.38 1.00 0.49
At least once a fortnight/Once a
month
49 (46.9) 20.62 1.53 (0.87–2.69)
Several days a week 68 (38.2) 19.36 1.32 (0.76–2.30)
Every day 56 (37.5) 19.55 1.40 (0.78–2.51)
Social support – rely on family/friends A little/not at all 33 (36.4) 17.48 1.00 0.84
A lot 214 (38.3) 18.16 1.06 (0.59–1.93)
Social support – open with friends/
family
Not at all 57 (36.8) 15.81 1.00 0.06
A little 93 (31.2) 13.86 0.90 (0.52–1.57)
A lot 97 (45.4) 24.72 1.54 (0.93–2.55)
Social support- confidantc No 16 (43.8) 20.91 1.00 0.49
Yes 226 (38.1) 18.05 0.74 (0.32–1.72)
Social capital – time with neighbours < once a month/not at all 65 (43.1) 18.80 1.00 0.88
At least once a fortnight/Once a
month
38 (34.2) 15.17 0.78 (0.41–1.49)
Several days a week 61 (37.7) 18.30 0.93 (0.54–1.59)
Every day 83 (36.1) 18.78 1.00 (0.60–1.67)
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sex differences in patterns of HIV disclosure, with
women more likely to disclose to multiple categories of
people [43]. The relationship between LTFU and the
combined openness and partner disclosure variable in
our sample, however, remained once sex was controlled
for (in a predominantly female sample).
Taken together, both the main effect of openness with
family and friends and the interaction between openness
with family and friends and partner disclosure suggest
that social support needs may be salient even when
medical needs are less pressing. Further investigation of
the relationship between social support and LTFU may
highlight the need to strengthen psychosocial support
services in pre-ART care. In sum, clinic attendance may
be motivated by both social and health needs.
Greater LTFU was associated with having an HIV-
negative partner rather than a partner who is HIV-positive
or of unknown status. It may be that HIV positive partners
are better able to support ongoing clinic attendance or
that having an HIV negative partner is a barrier to reten-
tion. Future qualitative studies could investigate this find-
ing further. LTFU was independently associated with
number of children. There was no clear linear pattern be-
tween the number of children and LTFU, however. The
category with the lowest LTFU rate in the final model was
having no children. The precision of this estimate was
low, due to the small number of childless individuals. A
greater sample size would allow for more exploration of
this and other effects. LFTU was also associated with a
history of previous CD4 tests. Individuals who were re-
cruited when they had received their first CD4 count had
greater LTFU than those who were already in HIV care
and had received previous CD4 counts. This result was
unsurprising as the latter individuals had already shown
their willingness and ability to return for at least one re-
peated CD4 test in pre-ART care.
Table 2 Psychosocial variables and loss-to-follow up in pre-ART care (Continued)
Social capital – neighbourhood crimed Common 108 (39.8) 18.85 1.00 0.38
Unusual 87 (33.3) 14.95 0.81 (0.51–1.29)
Rare 49 (42.9) 22.77 1.21(0.72–2.05)
Social capital - group participation No 197 (41.1) 20.32 1.00 0.07
Yes 50 (26.0) 10.69 0.58 (0.32–1.05)
Social capital – neighbours giving
time
No 63 (38.1) 16.42 1.00 0.50
Yes 184 (38.0) 18.72 1.16 (0.75–1.82)
Social capital – neighbours giving
money
No 74 (37.8) 15.81 1.00 0.42
Yes 173 (38.2) 19.24 1.19 (0.78–1.82)
Social capital –community working
together
Individual/neighbours or traditional
leaders or municipal/district leaders
taking lead
166 (34.9) 16.57 1.00 0.18
Traditional and local leaders
together taking lead
81 (44.4) 21.15 1.32 (0.88–2.00)
Relationship qualitye Low (0–23) 59 (42.4) 19.01 1.00 0.91
Mid (24–26) 68 (39.7) 19.26 0.95 (0.55–1.65)
High (27–30) 70 (38.6) 18.29 0.89 (0.52–1.52)
Most recent partner age differentialf Older 186 (36.6) 16.80 1.00 0.40
Same 26 (38.5) 19.87 1.08 (0.55–2.15)
Younger 34 (47.1) 26.21 1.45 (0.85–2.49)
Most recent partner location In neighbourhood 23 (43.5) 21.42 1.00 0.10
Out of neighbourhood 109 (45.0) 22.22 1.06 (0.54–2.08)
With participant 115 (30.4) 13.84 0.67 (0.33–1.34)
Most recent partner HIV disclosure No 92 (35.9) 18.15 1.00 0.69
Yes 155 (39.4) 18.03 1.09 (0.71–1.67)
Most recent partner HIV status Positive 95 (41.1) 18.95 1.00 0.10
Not known 138 (34.1) 16.14 0.78 (0.51–1.19)
Negative 14 (57.1) 34.60 1.78 (0.81–3.90)
an = 247 unless stated; bCompeting Risks Regression; cn = 242; dn = 244; en = 197 (for those with a current main partner at enrolment); fn = 246
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A number of variables (male sex, the receipt of gov-
ernment grants, never having been married and outward
migration) were not significantly associated with LTFU
in our analyses, despite being previously identified as as-
sociated in other studies in the literature, perhaps due to
insufficient statistical power. Some of these variables
may have been related to other exposures that were in
the final model (e.g., outward migration and the number
of previous CD4 counts). Sex has been associated with
time to ART-eligibility [44] in the same cohort, and travel
costs have been identified as the largest expense for those
in pre-ART care in the same programme [45]. Being un-
married and outward migration have both been shown to
be related to LTFU in other pre-ART samples [8, 10].
The LTFU rate is this study appeared to be lower than
those reported for individuals with a CD4 count of
>500 mm/cells3 in an earlier study on the programme
population [8]. Directly comparing between the studies
is difficult, however. We only recruited from three of the
17 clinics that offered HIV care in the local programme,
specifically those that were most accessible. In addition,
our study only included individuals who had returned
for the CD4 count that determined their eligibility for
ART. In the earlier study, all individuals were included
regardless of whether they had returned for their CD4
test result. Although the definition of LTFU was com-
parable in both studies, our longer follow-up period will
have made it more likely that some individuals will have
experienced symptoms as their CD4 count dropped [46].
This may have prompted clinic attendance. Finally, our
study was based on data from a later time period, during
which guidelines for ART eligibility changed signifi-
cantly. Alternatively, our lower LTFU rate may in part
have been due to prompting associated with on-going
participation in the prospective cohort study [12] that
involved interviews every six months either in clinic or
by phone. A more ideal study design would have been to
prospectively follow individuals in pre-ART care through
the programme only, however using routine programme
data would have meant that other data available to ex-
plore as factors associated with LTFU would have been
limited. Study retention was, however, separate from
ART programme retention, and did not rely on clinic at-
tendance. For example, 39 % of the 6 month cohort
study interviews were not conducted at the clinic [12].
Our sample was similar in demographic characteristics
to pre-ART patients in the HIV treatment and care
programme as a whole, including the sex ratio disparity
[8], and mortality rates were consistent with other pre-
ART studies [4]. Post-hoc analysis showed no differences
in estimates when we conducted the analysis separately
for those participants without a previous CD4 count
(n = 95) and those with a previous CD4 count (n = 152).
This study assessed a wider range of variables (particu-
larly psychosocial variables) than other studies and was
strengthened by a prospective cohort design with data
on clinic attendance collected over a four-year period.
Considerable effort was made to minimise ascertainment
Table 3 Final multivariable model of associations with loss-to-follow up in pre-ART care using Competing Risks Regression (n = 247)
Subhazard Ratio
(95 % CI)
P value of association
with LTFU
Adjusted Subhazard
Ratio (95 % CI)
P value of association
with LTFU
Age ≤37 1.00 0.01 1.00 0.01
>37 0.51 (0.32–0.83) 0.51 (0.30–0.87)
Sex Female 1.00 0.41 1.00 0.36
Male 1.27 (0.72–2.23) 1.31 (0.73–2.37)
Number of previous CD4 counts 0 1.00 0.04 1.00 0.01
1 0.89 (0.57–1.40) 0.76 (0.48–1.22)
2+ 0.49 (0.29–0.85) 0.43 (0.25–0.73)
Social support – open with friends/family Not at all 1.00 0.06 1.00 0.02
A little 0.90 (0.52–1.57) 0.81 (0.45–1.43)
A lot 1.54 (0.93–2.55) 1.57 (0.94–2.62)
Most recent partner HIV status Positive 1.00 0.10 1.00 0.01
Not known 0.78 (0.51–1.19) 0.77 (0.50–1.19)
Negative 1.78 (0.81–3.90) 2.40 (1.18–4.88)
Number of children None 1.25 (0.46–3.38) 0.03 0.68 (0.24–1.87) 0.04
1 child 2.34 (1.32–4.14) 2.05 (1.14–3.69)
2 children 1.99 (1.13–3.50) 1.71 (0.94–3.09)
3 children 1.34 (0.69–2.60) 1.14 (0.57–2.30)
4+ children 1.00 1.00
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bias (e.g., participant tracking in the context of the pro-
spective cohort study [12] and cross-checking outcomes
between databases). The Competing Risks regression ana-
lysis gave similar results to those produced by using Cox
regression. It is acknowledged, however, that there are
limitations with using Competing Risks regression, which
assumes conditional independence of different events.
Some of the variables measured at recruitment may
have changed over the study duration (e.g., openness
with family and friends). Both initial and intervening un-
measured factors may have influenced whether patients
were LTFU at the end of the study period (e.g., beliefs
about the consequences of attending clinic, symptoms,
nature of the patient-provider relationship, mood,
migration or alcohol use). Future studies could use a
larger sample and a theoretical framework of engage-
ment in care to select potentially explanatory variables,
(e.g., specific beliefs about care [35]), that might be
amenable to intervention.
Conclusion
In summary, this study showed that being more open
with family and friends, younger age, having fewer previ-
ous CD4 counts, number of children and most recent
partner’s HIV negative status were independently related
to higher rates of HIV treatment and care programme
LTFU in individuals in pre-ART care. These relationships
are important given the need to retain large numbers of
HIV-positive individuals who are not ART-eligible (specif-
ically those with a CD4 count of >500 cells/mm3) in long-
term care. We also showed that even though the rates of
LTFU may differ between those not yet eligible for ART
and those who are eligible and/or on treatment, some of
the predictors of LTFU may be similar [11].
Ethical approval and consent to participate
Ethical approval was obtained from KwaZulu-Natal
Department of Health, after review by the Biomedical
Research Ethics Committee at University of KwaZulu-
Table 4 Multivariable model of associations with loss-to-follow up in pre-ART care (n = 247) including composite social support and
partner disclosure variablea using Competing Risks regression
Subhazard Ratio
(95 % CI)
P value of association
with LTFU (LRT)
Adjusted Hazard
Ratio (95 % CI)
P value of association
with LTFU (LRT)
Age ≤37 1.00 0.01 1.00 0.02
>37 0.51 (0.32–0.83) 0.49 (0.28–0.87)
Sex Female 1.00 0.41 1.00 0.29
Male 1.27 (0.72–2.23) 1.38 (0.76–2.52)
Social support – open with
friends/family and partner disclosure
Not at all open and not
disclosed to partner
1.00 0.06 1.00 0.01
Not at all open and
disclosed to partner
3.40 (1.18–9.83) 3.03 (0.95–9.73)
A little open and not
disclosed to partner
2.55 (0.82–7.96) 2.72 (0.86–8.64)
A little open and disclosed
to partner
1.88 (0.65–5.49) 1.41 (0.44–4.53)
A lot open and not
disclosed to partner
3.84 (1.30–11.31) 4.22 (1..47–12.11)
A lot open and disclosed
to partner
3.48 (1.24–9.78) 3.12 (1.03–9.45)
Number of previous CD4 counts 0 1.00 0.04 1.00 0.01
1 0.89 (0.57–1.40) 0.71 (0.45–1.14)
2+ 0.49 (0.29–0.85) 0.43 (0.25–0.73)
Most recent partner HIV status Positive 1.00 0.10 1.00 0.02
Not known 0.78 (0.51–1.19) 0.74 (0.45–1.22)
Negative 1.78 (0.81–3.90) 2.18 (1.05–4.51)
Number of children None 1.25 (0.46–3.38) 0.03 0.69 (0.25–1.94) 0.02
1 child 2.34 (1.32–4.14) 2.23 (1.21–4.10)
2 children 1.99 (1.13–3.50) 1.88 (0.99–3.54)
3 children 1.34 (0.69–2.60) 1.15 (0.55–2.39)
4+ children 1.00 1.00
aRepresenting an interaction between openness with family/friends and partner disclosure
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